Human chorionic gonadotropin interactions with immobilized anti‐hCG studied by quartz‐crystal microbalance with dissipation monitoring

Chung, Natalie N.; Hamlin, Rebecca E.; Zwang, Theodore J.; Johal, Malkiat S.

doi:10.1002/jbm.a.34100

Cited by 7 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detected amount of hIgG by the anti-human biointerface and oriented anti-human biointerface (0.90 ± 0.09 and 1.28 ± 0.11 mg/m 2 , respectively) with D 33 - b -EGMA 137 passivation (Figures a and ) was good compared to other reported anti-human IgG biointerfaces based on cellulose , and to other hIgG binding surfaces ,, prepared on alkanethiol self-assembled monolayers and grafted copolymer brush surfaces. The results for adsorbed amount of hIgG and anti-hIgG are also comparable to those reported for other antibodies. , This clearly demonstrates that while the block copolymers provide the biointerface with much-needed surface passivation to avoid false responses, the functionality of the biointreface is not compromised or reduced by their use. Furthermore, as interest in utilization of cellulose-based products in biomedical applications increases it is important to understand their interactions with biomolecules, the only way to control and tailor the systems to the specific needs.…”

Section: Resultssupporting

confidence: 79%

“…The results for adsorbed amount of hIgG and anti-hIgG are also comparable to those reported for other antibodies. 54,55 This clearly demonstrates that while the block copolymers provide the biointerface with much-needed surface passivation to avoid false responses, the functionality of the biointreface is not compromised or reduced by their use. Furthermore, as interest in utilization of cellulose-based products in biomedical applications increases it is important to understand their interactions with biomolecules, the only way to control and tailor the systems to the specific needs.…”

Section: ■ Experimental Sectionmentioning

confidence: 89%

See 1 more Smart Citation

Control of Protein Affinity of Bioactive Nanocellulose and Passivation Using Engineered Block and Random Copolymers

Vuoriluoto

Orelma

Zhu

et al. 2016

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

We passivated TEMPO-oxidized cellulose nanofibrils (TOCNF) toward human immunoglobulin G (hIgG) by modification with block and random copolymers of poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA) and poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA). The block copolymers reversibly adsorbed on TOCNF and were highly effective in preventing nonspecific interactions with hIgG, especially if short PDMAEMA blocks were used. In such cases, total protein rejection was achieved. This is in contrast to typical blocking agents, which performed poorly. When an anti-human IgG biointerface was installed onto the passivated TOCNF, remarkably high affinity antibody-antigen interactions were observed (0.90 ± 0.09 mg/m(2)). This is in contrast to the nonpassivated biointerface, which resulted in a significant false response. In addition, regeneration of the biointerface was possible by low pH aqueous wash. Protein A from Staphylococcus aureus was also utilized to successfully increase the sensitivity for human IgG recognition (1.28 ± 0.11 mg/m(2)). Overall, the developed system based on TOCNF modified with multifunctional polymers can be easily deployed as bioactive material with minimum fouling and excellent selectivity.

show abstract

Section: Resultssupporting

confidence: 79%

Section: ■ Experimental Sectionmentioning

confidence: 89%

Control of Protein Affinity of Bioactive Nanocellulose and Passivation Using Engineered Block and Random Copolymers

Vuoriluoto

Orelma

Zhu

et al. 2016

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Nevertheless, in the patient with the trophoblastic tumor, the hCG secretion can increase up to 10,000 mIU/mL at 5 weeks, 1000 mIU/mL at 8 weeks, or detectable at 24 weeks after the evacuation of the mole, at which point is recommended for the patient to undergo chemotherapy [133,135]. Several studies reported the detection of hCG in biosensor platforms, such as in magnetometer-based biosensor [8,[136][137][138], plasmonic-based biosensor [139,140], QCM platform [141], and FET-based device [142].…”

Section: Single Biomarkermentioning

confidence: 99%

The Challenges of Developing Biosensors for Clinical Assessment: A Review

et al. 2021

View full text Add to dashboard Cite

Emerging research in biosensors has attracted much attention worldwide, particularly in response to the recent pandemic outbreak of coronavirus disease 2019 (COVID-19). Nevertheless, initiating research in biosensing applied to the diagnosis of diseases is still challenging for researchers, be it in the preferences of biosensor platforms, selection of biomarkers, detection strategies, or other aspects (e.g., cutoff values) to fulfill the clinical purpose. There are two sides to the development of a diagnostic tool: the biosensor development side and the clinical side. From the development side, the research engineers seek the typical characteristics of a biosensor: sensitivity, selectivity, linearity, stability, and reproducibility. On the other side are the physicians that expect a diagnostic tool that provides fast acquisition of patient information to obtain an early diagnosis or an efficient patient stratification, which consequently allows for making assertive and efficient clinical decisions. The development of diagnostic devices always involves assay developer researchers working as pivots to bridge both sides whose role is to find detection strategies suitable to the clinical needs by understanding (1) the intended use of the technology and its basic principle and (2) the preferable type of test: qualitative or quantitative, sample matrix challenges, biomarker(s) threshold (cutoff value), and if the system requires a mono- or multiplex assay format. This review highlights the challenges for the development of biosensors for clinical assessment and its broad application in multidisciplinary fields. This review paper highlights the following biosensor technologies: magnetoresistive (MR)-based, transistor-based, quartz crystal microbalance (QCM), and optical-based biosensors. Its working mechanisms are discussed with their pros and cons. The article also gives an overview of the most critical parameters that are optimized by developing a diagnostic tool.

show abstract

“…Nevertheless, in the patient with the trophoblastic tumor, the hCG secretion can increase up to 10,000 mIU/mL at 5 weeks, 1000 mIU/mL at 8 weeks, or detectable at 24 weeks after the evacuation of the mole, at which point is recommended for the patient to undergo chemotherapy [136,137]. Several studies reported the detection of hCG in biosensor platforms, such as in magnetometer-based biosensor [8,[138][139][140], plasmonic-based biosensor [141,142], QCM platform [143],…”

Section: Single Biomarkermentioning

confidence: 99%

The challenges of developing biosensors for clinical assessment: a review

Prabowo¹

2021

Preprint

View full text Add to dashboard Cite

Emerging research in biosensors has attracted much attention worldwide, particularly in re-sponse to the recent pandemic outbreak of coronavirus disease 2019 (COVID-19). Neverthe-less, initiating research in biosensing applied to the diagnostic of diseases is still challenging for researchers, either from the preferences of biosensor platforms, selection of biomarkers, detection strategies, and other aspects (e.g., cutoff values) to fulfill the clinical purpose. There are two sides to the development of a diagnostic tool: the biosensor development side and the clinical side. From the development side, the research engineers seek the typical characteristics of a biosensor: sensitivity, selectivity, linearity, stability, and reproducibility. On the other side are the physicians that expect a diagnostic tool that provides fast acquisition of patient in-formation to obtain an early diagnostic or an efficient patient stratification, which conse-quently allows making assertive and efficient clinical decisions. The development of diagnostic devices always involves assay developer researchers, working as pivots to bridge both sides, which role is to find detection strategies suitable to the clinical needs. First, by understanding the intended use of the technology and its basic principle; second, the preferable type of test: qualitative or quantitative, sample matrix challenges, biomarker(s) threshold (cutoff value), and if the system requires a mono or multiplex assay format. This review highlights the challenges for the development of biosensors for clinical assessment and its broad application in multidisciplinary fields. This review paper highlights the following biosensor technologies: magnetoresistive (MR)-based, transistor-based, quartz crystal microbalance (QCM), and op-tical-based biosensors. Its working mechanisms are discussed with their pros and cons. The article also gives an overview of the most critical parameters that are optimized by developing a diagnostic tool.

show abstract

Human chorionic gonadotropin interactions with immobilized anti‐hCG studied by quartz‐crystal microbalance with dissipation monitoring

Cited by 7 publications

References 18 publications

Control of Protein Affinity of Bioactive Nanocellulose and Passivation Using Engineered Block and Random Copolymers

Control of Protein Affinity of Bioactive Nanocellulose and Passivation Using Engineered Block and Random Copolymers

The Challenges of Developing Biosensors for Clinical Assessment: A Review

The challenges of developing biosensors for clinical assessment: a review

Contact Info

Product

Resources

About